| Balance sheet (USD) | Q2 2026 ended Jun 27, 2026 | Q1 2026 ended Mar 28, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 27, 2025 | Q2 2025 ended Jun 28, 2025 | Q1 2026 ended Mar 29, 2025 | Q4 2025 ended Dec 31, 2024 | Q3 2025 ended Sep 28, 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.06B | 3.25B | 9.85B | 1.98B | 4.58B | 4.13B | 4.01B | 4.64B |
| Short-term investments | 0 | 2.00M | 253.00M | 1.56B | 1.81B | 1.81B | 1.56B | 2.00B |
| Receivables | 9.45B | 9.20B | 8.90B | 8.91B | 8.59B | 8.46B | 8.19B | 8.26B |
| Inventory | 5.63B | 5.50B | 5.42B | 5.75B | 5.56B | 5.22B | 4.98B | 5.43B |
| Total current assets | 23.36B | 22.32B | 28.71B | 22.30B | 24.58B | 23.38B | 22.14B | 23.78B |
| Property, plant and equipment | 10.76B | 10.66B | 10.56B | 10.18B | 9.63B | 9.33B | 9.31B | 9.41B |
| Goodwill and intangibles | 73.44B | 74.33B | 65.20B | 65.53B | 62.40B | 61.82B | 61.39B | 62.99B |
| Total assets | 113.17B | 113.28B | 110.34B | 103.02B | 101.23B | 99.04B | 97.32B | 100.36B |
| Accounts payable | 3.27B | 3.34B | 3.62B | 3.12B | 2.98B | 3.05B | 3.08B | 2.61B |
| Total current liabilities | 15.07B | 14.62B | 15.19B | 14.89B | 12.72B | 13.17B | 13.33B | 14.60B |
| Long-term debt | 39.18B | 40.07B | 35.85B | 31.86B | 33.02B | 31.37B | 29.06B | 31.20B |
| Total liabilities | 60.49B | 61.35B | 56.94B | 52.00B | 50.72B | 49.65B | 47.74B | 51.37B |
| Retained earnings | 62.19B | 60.63B | 59.16B | 57.35B | 55.90B | 54.45B | 53.10B | 51.42B |
| Shareholders' equity | 52.68B | 51.93B | 53.41B | 51.02B | 50.51B | 49.39B | 49.58B | 48.99B |
| Total debt | 42.55B | 43.16B | 39.38B | 35.68B | 35.23B | 34.19B | 31.27B | 35.31B |
| Net debt | 38.48B | 39.91B | 29.53B | 33.70B | 30.65B | 30.05B | 27.27B | 30.67B |
From Thermo Fisher Scientific's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.